← Back to Search

Monoclonal Antibodies

Bevacizumab for Glioblastoma

Phase 1

Recruiting

Research Sponsored by Global Neurosciences Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No IV chemotherapy for three weeks prior to treatment under this research protocol and no external beam radiation for four weeks prior to treatment under this research protocol

Patients must have adequate hematologic reserve

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing a new way to give chemotherapy to people with a certain type of brain tumor. The hope is that it will help them live longer.

Who is the study for?

Adults over 18 with a specific brain cancer called Glioblastoma Multiforme that has come back after surgery can join. They should be in good enough health to understand the study and give consent, have normal blood clotting, not have had recent chemotherapy or radiation, and agree to use birth control.Check my eligibility

What is being tested?

The trial is testing Bevacizumab delivered directly to the brain tumor through an artery. This method aims to increase drug concentration at the tumor site while reducing whole-body side effects by using a catheter from the leg artery up into the brain.See study design

What are the potential side effects?

Bevacizumab may cause bleeding, high blood pressure, tiredness, headaches, and wound healing problems. The direct infusion technique might reduce these systemic side effects but could include risks associated with catheter placement.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I haven't had IV chemotherapy in the last 3 weeks or radiation in the last 4 weeks.

Select...

My blood counts are within a healthy range.

Select...

My grade IV brain tumor has come back after being completely removed.

Select...

My diagnosis is glioblastoma.

Select...

I am older than 18 years.

Select...

It has been over four weeks since my last surgery.

Select...

I can care for myself and am expected to live for at least three more months.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants with Adverse Events as a Measure of Safety

Secondary outcome measures

Tumor Response

Side effects data

From 2015 Phase 4 trial • 45 Patients • NCT02036424

22%

vitreous hemorrhage

17%

worsening of cataract

posterior capsule opacification

vitreous syneresis

cranial nerve VI palsy

bradycardia

pneumonia

pyelonephritis

colon cancer

100%

80%

60%

40%

20%

Study treatment Arm

Bevacizumab

Ozurdex

Trial Design

1Treatment groups

Experimental Treatment

Group I: Intra Arterial BevacizumabExperimental Treatment1 Intervention

Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bevacizumab

2013

Completed Phase 4

~5280

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

Global Neurosciences InstituteLead Sponsor

2 Previous Clinical Trials

70 Total Patients Enrolled

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT02285959 — Phase 1

Glioblastoma Research Study Groups: Intra Arterial Bevacizumab

Glioblastoma Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT02285959 — Phase 1

Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02285959 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper threshold of individuals involved in this research?

"Affirmative. Per information found on clinicaltrials.gov, this clinical trial is actively seeking out enrollees and was first posted June 1st 2014 with the last update occuring August 8th 2022. Altogether, 30 patients are needed from a single medical centre for participation in this study."

Answered by AI

What medical conditions has Bevacizumab been found to assist with?

"Bevacizumab is traditionally used to treat cancer, however it can also be taken for conditions such as recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer after the initial surgery and locally advanced nonsquamous non-small cell lung cancers."

Answered by AI

Have there been further investigations concerning Bevacizumab?

"Currently, 355 investigations are being conducted using Bevacizumab. Out of these, 89 have reached the third clinical trial phase. Although the majority of trials take place in Taibei, Taiwan, a total of 17017 sites actively participate in this research effort."

Answered by AI

Are there any open opportunities for individuals to participate in this trial?

"Affirmative. Clinicaltrials.gov provides documentation that this clinical study, which was first posted in June 2014, is presently recruiting for 30 individuals at one medical site. The trial has been most recently updated on August 8th 2022."

Answered by AI